High dose vs low dose irradiation of the subventricular zone in patients with glioblastoma—a systematic review and meta-analysis

• Published in: Cancer management and research Vol. 11; pp. 6741 - 6753
• Main Authors: Şuşman, Sergiu, Leucuţa, Daniel-Corneliu, Kacso, Gabriel, Florian, Ştefan loan
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.07.2019; Dove; Dove Medical Press
• Subjects: Comparative analysis; glioblastoma multiforme; Glioblastomas; Gliomas; Medical research; neural stem cells; Radiation (Physics); radiation therapy; Radiotherapy; Review; Stem cell transplantation; Stem cells; survival; Romania; glioblastoma; neural stem cells; radiation therapy; survival
• ISSN: 1179-1322; 1179-1322
• DOI: 10.2147/CMAR.S206033

The published data indicate that the irradiation of the subventricular zone (SVZ) might play a role in the treatment of patients with glioblastoma (GBM). We aimed to determine whether radiation treatment doses (high vs low) applied to the SVZ can lead to an increase in progression free survival (PFS) and overall survival (OS). We undertook a systematic review and meta-analysis according to the PICOS research criteria of patients with glioblastoma which received high doses compared to low doses in order to determine if they have a better survival in observational and experimental studies. Our survey of the literature yielded 2573 unique records. After screening, 17 were assessed for eligibility, and in the end 8 were included in the qualitative and 4 in the quantitative analysis. Subjects who received higher doses of ipsilateral SVZ (iSVZ) irradiation had a statistically significant better PFS than those receiving lower doses (HR 0.58 [95% CI 0.42-0.82], =0.002). Subjects receiving higher doses of contralateral SVZ (cSVZ) irradiation did not have a statistically significant better PFS than those receiving lower doses (HR =0.89 [95% CI 0.35-2.26], =0.81). Also for OS the subjects receiving higher doses to the iSVZ did not have a statistically significant better survival than those receiving lower doses (HR =0.75 [95% CI 0.51-1.11], =0.15). The data indicate a possible involvement of the SVZ in the onset and progression of the GBM, as well as a possible role of the SVZ in radiation therapy.